Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176526
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ramos Izquierdo, Ricard | - |
dc.contributor.author | Macía, Ivan | - |
dc.contributor.author | Navarro Martin, Arturo | - |
dc.contributor.author | Déniz, Carlos | - |
dc.contributor.author | Rivas, Francisco | - |
dc.contributor.author | Ureña Lluveras, Anna | - |
dc.contributor.author | Masuet Aumatell, Cristina | - |
dc.contributor.author | Moreno, Camilo | - |
dc.contributor.author | Nadal, Ernest | - |
dc.contributor.author | Escobar Campuzano, Ignacio | - |
dc.date.accessioned | 2021-04-20T15:29:44Z | - |
dc.date.available | 2021-04-20T15:29:44Z | - |
dc.date.issued | 2021-03-02 | - |
dc.identifier.issn | 1471-2466 | - |
dc.identifier.uri | http://hdl.handle.net/2445/176526 | - |
dc.description.abstract | Background: Tthe aim of this study was to assess the effect of the lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on overall survival and disease-free survival in patients with lung cancer treated with radical surgery. Methods: we performed a retrospective review of patients with lung cancer who prospectively underwent radical resection between 2004 and 2012. Blood samples were taken as part of the preoperative workup. The inflammatory markers studied were absolute values of lymphocytes, monocytes, neutrophils and platelets, with subsequent calculation of ratios. Median follow-up was 52 months. Results: two hundred and sixty-eight patients underwent surgery, of whom 218 (81.3%) were men. Mean age was 62.9 ± 8.7 years. A lymphocyte-to-monocyte ratio ≥ 2.5 was independently associated with longer disease-free survival (hazard ratio [HR] 0.476 (0.307-0.738), p = 0.001) and longer overall survival (HR, 0.546; 95% CI: 0.352-0.846; p = 0.007), in models adjusted for age, sex, stage, and type of resection. No other systemic inflammatory marker showed a significant association. Conclusion: preoperative LMR is an independent prognostic factor of overall survival and recurrence-free survival in patients with surgically-resected early stage lung cancer. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s12890-021-01446-1 | - |
dc.relation.ispartof | BMC Pulmonary Medicine, 2021, vol. 21, num. 1, p. 75 | - |
dc.relation.uri | https://doi.org/10.1186/s12890-021-01446-1 | - |
dc.rights | cc-by (c) Ramos Izquierdo, Ricard et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Càncer de pulmó | - |
dc.subject.classification | Sang | - |
dc.subject.classification | Limfòcits | - |
dc.subject.other | Lung cancer | - |
dc.subject.other | Blood | - |
dc.subject.other | Lymphocytes | - |
dc.title | Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 711051 | - |
dc.date.updated | 2021-04-20T15:29:44Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33653309 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Infermeria Fonamental i Clínica) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
711051.pdf | 1.06 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License